Costagliola C, Fasano M L, Iuliano G, Ferrara L A
Eye Clinic, 1st Medical School, University of Naples, Italy.
Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:97-9. doi: 10.1007/BF00053437.
There is evidence that some antihypertensive drugs, such as beta blockers, are effective in reducing intraocular pressure (IOP) and are commonly used in the medical treatment of glaucoma. The aim of this study was to evaluate the effects of the anti-serotonergic agent ketanserin, which has associated alpha 1-blocking properties, on IOP in normotensive and hypertensive eyes. The first part of the study was performed in six arterial hypertensive patients (mean +/- SD blood pressure 156/102 +/- 10/6 mmHg) with a pretreatment IOP in the normal range (15.7 +/- 1 mmHg). Both blood pressure and IOP were measured at baseline and at 1 hour intervals up to 3 hours following the oral administration of ketanserin 20 mg or placebo, given in a randomized manner. Three hours after ketanserin treatment, mean systolic and diastolic blood pressures dropped by 10/5 mmHg and mean IOP was reduced by 2.7 mmHg; after placebo, no change was observed in these variables. Thereafter, four normotensive patients with chronic open-angle glaucoma (IOP = 22.8 mmHg) were given 20 mg ketanserin orally. Three hours after administration, a 22% reduction in mean IOP occurred (-5.8 mmHg), with a concomitant reduction in mean systolic blood pressure of 13.0 mmHg. These results indicate that ketanserin treatment reduces IOP and systemic blood pressure. Further, long-term studies are needed in order to confirm the efficacy of ketanserin in the medical treatment of ocular hypertension.
有证据表明,一些抗高血压药物,如β受体阻滞剂,在降低眼压(IOP)方面有效,常用于青光眼的药物治疗。本研究的目的是评估具有α1阻断特性的抗5-羟色胺能药物酮色林对正常血压和高血压眼睛眼压的影响。研究的第一部分在6名动脉性高血压患者(平均±标准差血压为156/102±10/6 mmHg)中进行,其治疗前眼压在正常范围内(15.7±1 mmHg)。以随机方式口服20 mg酮色林或安慰剂后,在基线以及给药后1小时间隔直至3小时测量血压和眼压。酮色林治疗3小时后,平均收缩压和舒张压下降了10/5 mmHg,平均眼压降低了2.7 mmHg;服用安慰剂后,这些变量未观察到变化。此后,4名患有慢性开角型青光眼(眼压=22.8 mmHg)的正常血压患者口服20 mg酮色林。给药3小时后,平均眼压降低了22%(-5.8 mmHg),同时平均收缩压降低了13.0 mmHg。这些结果表明,酮色林治疗可降低眼压和全身血压。此外,需要进行长期研究以证实酮色林在治疗高眼压症方面的疗效。